Developing as a promising advance in the battle against obesity, the drug is capturing considerable buzz. This treatment combines effects of two established GLP-1 binding agonists, liraglutide, with an unique glucose-dependent incretin component. Preliminary patient findings have shown significant fat loss in individuals with a high BMI , poten… Read More